Key result
Diabetes is linked to ~2- to 4-fold higher cardiovascular disease risk.
Why the study?
Although diabetes is defined by microvascular complications that Intensive glycemic control reduces, cardiovascular disease is the greatest cause of death in people with diabetes, motivating evaluation of the implications of the ACCORD, ADVANCE, and VA Diabetes trials for preventing cardiovascular events.
Does intensive glycemic control prevent cardiovascular events and microvascular complications in patients with diabetes?
Does intensive glycemic control prevent cardiovascular events and microvascular complications in patients with diabetes?
Answers are grounded in this paper and cite their sources.
Intensive glycemic control substantially reduces microvascular complications in diabetes across a continuous A1c spectrum without a glycemic threshold, framing the evaluation of cardiovascular event prevention in major diabetes trials.
D iabetes is defined by its association with hyperglycemia- specific microvascular complications; however, it also imparts a 2-to 4-fold risk of cardiovascular disease (CVD).Although microvascular complications can lead to significant morbidity and premature mortality, by far the greatest cause of death in people with diabetes is CVD.4][5] In the Diabetes Control and Complications Trial (DCCT), there was an Ϸ60% reduction in the development or progression of diabetic retinopathy, nephropathy, and neuropathy between the intensively treated group (goal A 1c , Ͻ6.05%; mean achieved A 1c , Ϸ7%) and the standard group (A 1c , Ϸ9%) over an average of 6.5 years.The relationship between glucose control (as reflected by the mean on-study A 1c value) and risk of complications was log-linear and extended down to the normal A 1c range (Ͻ6%) with no threshold noted.In the UK Prospective Diabetes Study (UKPDS), participants newly diagnosed with type 2 diabetes were followed up for 10 years, and intensive control (median A 1c , 7.0%) was found to reduce the overall microvascular complication rate by 25% compared with conventional treatment (median A 1c , 7.9%).Here, too, secondary analyses showed a continuous relationship between the risk of microvascular complications and glycemia extending into the normal range of A 1c , with no glycemic threshold.
No takes yet. Share an insight, caveat, or question.
Skyler et al. (2008) conducted a review in Diabetes mellitus and cardiovascular disease. Intensive glycemic control vs. Standard or conventional glycemic control (mean HbA1c ~9% in DCCT; median HbA1c 7.9% in UKPDS) was evaluated on Prevention of cardiovascular events and microvascular complications (diabetic retinopathy, nephropathy, and neuropathy). Intensive glycemic control reduced microvascular complications by ~60% in DCCT and by 25% in UKPDS.
Synapse has enriched 10 related papers. Consider them for comparative context: